Dr Ferrone highlighted recent results on a prospective series of 48 borderline resectable patients which was published in JAMA Oncology.
Median Progression Free Survival (PFS) was reported at 37.7 months for all patients – and notably for those patients able to undergo resection + IORT (32/48 – 67%) the Progression Free Survival (PFS) was reported at 48.6 months.
A similar study for locally advanced patients is expected to publish shortly.
These results further reinforce the results that:
- Armed with IORT, significantly more patients can benefit from localized treatment with an opportunity for R0 resection
- With recent improvements in systemic therapy, the importance of local control has increased for this patient population.
- Intensive neoadjuvant therapy along with aggressive surgical exploration, appears to result in a significant survival benefit for these patients
- There are no reported increases of toxicity or morbidity in patients treated with IORT and the total procedure adds around 30 minutes (skin to skin) to the surgical procedure
The PACER trial which is intended to translate the Mass General Hospital protocol from a single institution to a multi-institution setting is expected to begin recruiting patients before the end of 2018.
To read more and access the full article click here
Why not visit the Intra-Op Virtual Exhibition stand on RadPro 365 live to see other IntraOp products and service